Jenny Howell appointed Chief Operating Officer

Jul 2, 2019

Jenny Howell joins Thirty Group as Chief Operating Officer. Jenny has more than 20 years’ experience in the biotech and pharmaceutical industry, most recently with AstraZeneca/MedImmune where she held a number of senior leadership positions including Chief of Staff to the Chief Medical Officer, Late Stage Development, and Head of Portfolio Strategy Management for Respiratory. Prior to joining AstraZeneca, Jenny was a Product Development Manager at Alizyme Therapeutics an AIM listed virtual drug development company.

Jenny is an accomplished pharmaceutical leader with an outstanding track record in defining and implementing strategic business processes and pharmaceutical product development plans, across a broad range of therapeutic areas. Jenny is highly skilled in project, portfolio and alliance management, delivering key strategic business objectives within multidisciplinary cross functional structures.

30 TECHNOLOGY is developing and defining new models of care to treat many serious medical conditions by enhancing the body’s healing and defence mechanisms.

30 TECHNOLOGY Therapeutic Nitric Oxide